SILVER ANNIVERSARY&mdash;INVITED EDITORIAL
A Quarter Century of Toxicologic Pathology:
A Personal Perspective Toxicologic Pathology is celebrating 25 years of publication by the Society of Toxicologic Pathologists (STP) , which makes its longevity in the field about the same as mine. The excellent debate on the use of the mouse in . safety assessment at the XV International Symposium, and in Vol. 24, No. 6 of the Journal, transported me back to 1973, when I first entered the field of toxicologic pathology. The National Cancer Act had recently been passed by Congress in 1971, and a National Cancer Institute (NCI) carcinogenesis screening program, which was started about 1962, suddenly became a major testing program with high levels of funding and very high public and political visibility, i.e., The Carcinogenesis Bioassay Program (eventually to become the National Toxicology Program [NTP] ). When I joined the NCI in 1973, there was already a dispute about the use of the mouse in testing, but there were inadequate data to resolve the issue based on evidence. Today, there are abundant data and there is still dispute, but now the STP provides the ideal forum for this debate and perhaps, ultimately, a resolution.
My task at the NCI was to head up the new Tumor Pathology Section and set up a pathology program, although when I arrived there were already several hundred chemicals on chronic test in mice and rats in several contract laboratories, with more to be added every year.
There were no pathology protocols or standards, and the numbers of pathologists working under contract to the Program were far too few. And of course, in 1973, there were no standardized nomenclature or diagnostic criteria. Toxicologic pathologists were about to face their first major challenge on a national scale, and the outcome could resonate for many years.
The pathology protocol that we developed followed standard pathology procedures, and thus required complete gross necropsies performed or supervised by qualified pathologists. Complete histopathologic examinations on all animals were also required. It was met by a firestorm! Many then involved in carcinogenesis testing (mostly nonpathologists) did not believe this was necessary ; some felt it was impossible to accomplish, and if accomplished, it would bankrupt the country. I even heard some express the view that merely careful gross necropsies would detect any carcinogen that was of potential concern to humans. NTP later tried abbreviated protocols, but returned to standard procedures. It may remain for history to judge whether these complete protocols have been worth the effort and cost.
Then, as now, there was no certification for toxicologic pathologists in 1973, and as the result of these pathology From 1973 -1977 Squire was Head of The Tumor Pathology Section and Director of The Carcinogenesis Testing Program at the National Cancer Institute. He is currently Professor of Comparative Medicine at The Johns Hopkins University School of Medicine, Baltimore, Maryland. z requirements, there was suddenly a severe shortage of board-certified veterinary pathologists in the United States. If you were a trainee in one of the recognized veterinary pathology training programs in the country, it was a great time to be alive! What became infamously known as the &dquo;NCI Bioassay pathology backlog&dquo; was ultimately completed (under considerable public and political scrutiny), thanks primarily to Dawn Goodman who had joined me at NCI and several toxicologic pathology pioneers in the Washington area private sector who came to our aid. (Except for the remarkable Charlie Barron [deceased], who provided wisdom in all matters, I will not mention names. But we old-timers know who they are.) They saved the good --
__ __ name of toxicologic pathology at that time, and may have given us our present and our future. Looking back on issues and problems and how we dealt with them two decades ago, I must conclude that safety assessment has recently entered an age of reason or enlightenment, in no small measure as the result of progress in toxicologic pathology. Our primary preoccupations in 1973, aside from the logistics of massive numbers of necropsies, histopathologic evaluations, record keeping, and reporting, were diagnostic criteria and nomenclature and study interpretation. Both of these activities were undertaken by committee, and our conclusions were sometimes challenged by affected industries, as they are today at the NTP But at that time, before Pathology Working Groups (PWGs), even judges and lawyers attempted to resolve disagreements among pathologists, once to the point of requesting a microscope in court during a regulatory hearing so the judge could view the slides in question. This resolved nothing except to demonstrate to the judge that the pathologists were, in fact, looking at the same lesions, not different ones, and the dispute resulted from differences in interpretation. He had apparently missed that important point. My first attempt to resolve a major dispute was a pathology workshop on rat liver tumors held in 1974. It was prompted by disagreements over lesions induced by several chlorinated compounds. That effort produced the novel term &dquo;neoplastic nodule,&dquo; which, upon publication, also produced a firestorm. There have been several versions circulating about the birth of the &dquo;neoplastic nodule.&dquo; The straight story from an eyewitness is as follows: The term was a compromise among the 20 participating pathologists regarding a lesion today classified as an adenoma, which in 1974 was often diagnosed as &dquo;hyperplastic nodule.&dquo; The lesion was thus dismissed as a nontumor by regulatory agencies. A deadlock in our deliberations was broken by a reading of the primary definition of hyperplasia in Stedman's Medical Dictionary as follows: &dquo;an increase in number of cells in a tissue or organ, excluding tumor formation, whereby the bulk of the part or organ is increased.&dquo; Thereafter, a consensus was reached that the liver lesion in question was a neoplasm rather than hyperplasia, but we could not reach agreement on benign versus malignant. Although the majority were in favor of the term &dquo;adenoma,&dquo; a minority objected because they felt the lesion was already committed to malignant progression, and &dquo;neoplastic nodule&dquo; was a compromise that we all could agree upon. Looking back, the term had a colorful and surprisingly long life. But I think all 20 of the participants would now agree that the STP Guides for Toxicologic Pathology and pathology working groups are clearly a better way to handle these things. Shortly after that rat liver workshop, Dawn Goodman set up a pathology peer-review system for the NCI Bioassay Program that essentially established the PWG process.
Much like the present, teams of toxicologists, pathologists, statisticians and others interpreted NCI bioassays and prepared reports. Initially, we naively thought we were judging and reporting only the carcinogenicity in test animals and not the relevance to humans. These bio-assays, we said, were not designed as a basis for regulation. But our folly became evident when the NCI released the first positive report (on trichloroethylene) as a &dquo;Memo of Alert&dquo; (in retrospect, an ill-considered title), and it immediately appeared in the New York Times.
There followed yet a third firestorm, since among other uses, trichloroethylene was used to decaffeinate some very popular brands of coffee, and, thus, the Delaney Clause could be involved. That was the end of our naivete, and what we thought was pure, although crude, science became tainted by politics.
Neither we nor regulators (who could not ignore our results) could objectively consider the relevance to humans of the bioassay results in any depth, since our knowledge of mechanisms in most cases was nil. Initially, there was not even pathologic or other data from acute or subchronic studies to accurately judge toxicity or identify target organs. The policy that animal data were relevant to humans was a foregone conclusion because the specter of the Delaney Clause rendered dose and mechanism considerations in animal studies irrelevant to safety assessment. Fortunately, scientists continued to investigate mechanisms even though no regulatory benefits were immediately evident.
It became apparent early in the program that there were many more positive compounds than had been anticipated, including some that were complete surprises. The prevailing view had been that there were relatively few chemical carcinogens in the environment and that most could be removed. I remember once expressing the view that anything that chronically increased cell proliferation in a target tissue could probably be carcinogenic under certain conditions. A few of those present nodded in tentative agreement, but most rejected it (and me) as blasphemous.
A few major policy debates in the '70s that have largely been resolved linger in my memory. One was that animal carcinogenicity tests would soon be extinct and replaced by genotoxicity assays, since genetic damage was the mechanism of carcinogenesis. Apparently, this was an oversimplification (as most pathologists suspected). Another was that given sufficient government dollars, enough animal tests could be conducted to rid the world of carcinogens. I remember receiving a call from a member of Congress asking me how many more dollars I needed to meet that goal. Meanwhile, in the NCI, we were planning to reduce the numbers of tests and to concentrate more on mechanisms, since animal carcinogens were rapidly accumulating, with little understanding of the relevance of the findings. Happily, the NTP has apparently pursued that policy. In fact, there were not enough pathologists (or other talent and facilities) available at the time to test more chemicals. In many ways it is amazing to consider where toxicologic pathology is today, a relatively few years after its beginnings. There are not many specialties that have progressed from birth to maturity in 25 years. The founders and members of this Society, the Journal editors, and the contributors should be very gratified. Those of us who have lived through the infancy and adolescence can also envy those entering the field today. They can design, di-agnose, interpret, extrapolate, and regulate based upon knowledge of at least some mechanisms rather than purely upon empirical evidence. This has been the goal of safety assessment since well before STP was born.
If, over the last 25 years, STP had done nothing more than develop the Journal, which has become highly respected throughout the world, and the Guides For Toxicologic Pathology, it would have fulfilled major needs and justified its existence. If the Society were to ask me today for my opinion about future directions (which it has not), I would probably say that training of toxicologic pathologists and maintaining the integrity and effectiveness of PWGs are two of the most important challenges the specialty faces. Particularly if there is no certifying examination in toxicologic pathology, the Society should consider developing guidelines for, and perhaps monitoring of, training. It is also imperative that private funding for training be developed and encouraged, since govern-ment support for residency training has virtually disappeared. The private funding could, perhaps, also be administered by the Society.
Finally, lest we forget our origins, dose-response relationships will likely remain at the core of safety assessment for the foreseeable future, and pathologists make the diagnoses that produce the dose-response data. Expert pathologic diagnosis, therefore, remains a vital and unique function of our specialty, even amidst the increasing importance of molecular biology. Pathology Working Groups have been widely accepted because they have resolved diagnostic disputes in a credible, objective manner. This is an important role and responsibility for toxicologic pathology in safety assessment, and it requires the commitment and support of all of us.
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